Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ziv-aflibercept in Ocular Disease
NCT02486484Phase 2Unknown
- Sponsor
- Rafic Hariri University Hospital
- Start
- Mar 2015
- Primary completion
- May 2019
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of aflibercept in neovascular age-related macular degeneration (NVAMD), diabetic macular edema (DME), retinal vein occlusion (RVO), diabetic retinopathy (DR), choroidal neovascularization (CNV), sponsored by Rafic Hariri University Hospital. Status: unknown.
02
Drugs
aflibercept
03
Conditions
neovascular age-related macular degeneration (NVAMD)diabetic macular edema (DME)retinal vein occlusion (RVO)diabetic retinopathy (DR)choroidal neovascularization (CNV)
Beyond the preview
Go deeper on NCT02486484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02486484.